Investigations on the stereoselectivity of the phase II metabolism of the 3,4-methylenedioxyethylamphetamine (MDEA) metabolites 3,4-dihydroxyethylamphetamine (DHEA) and 4-hydroxy-3-methoxyethylamphetamine (HMEA)

Toxicology Letters

Volumn 212, Issue 1, 2012, Pages 38-47

  Schwaninger, Andrea E ^a,c   Meyer, Markus R ^a   Zapp, Josef ^b   Maurer, Hans H ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

^c UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Glucuronidation; MDEA; Phase II metabolism; Stereoselectivity; Sulfation

Indexed keywords

4 HYDROXY 3 METHOXYETHYLAMPHETAMINE; AMPHETAMINE DERIVATIVE; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 2B15; GLUCURONOSYLTRANSFERASE 2B17; GLUCURONOSYLTRANSFERASE 2B7; N ETHYL 3,4 METHYLENEDIOXYAMPHETAMINE; PRASTERONE; SULFOTRANSFERASE; SULFOTRANSFERASE 1A1; SULFOTRANSFERASE 1A3; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CHIRALITY; CONTROLLED STUDY; CYTOSOL; DRUG METABOLISM; ENANTIOMER; ENZYME KINETICS; GAS CHROMATOGRAPHY; GLUCURONIDATION; HUMAN; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; MASS SPECTROMETRY; METABOLITE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; STEREOCHEMISTRY; SULFATION; SYNTHESIS;

3,4-METHYLENEDIOXYAMPHETAMINE; AMPHETAMINES; ANIMALS; DESIGNER DRUGS; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; LIVER; MICROSOMES, LIVER; RATS; STEREOISOMERISM; SULFOTRANSFERASES;

RATTUS;

EID: 84861390943     PISSN: 03784274     EISSN: 18793169     Source Type: Journal    
DOI: 10.1016/j.toxlet.2012.04.021     Document Type: Article

References (36)

1. Brunnenberg M., Kovar K.A. Stereospecific analysis of ecstasy-like N-ethyl-3,4-methylenedioxyamphetamine and its metabolites in humans. Journal of Chromatography. B, Biomedical Sciences and Applications 2001, 751:9-18.
2. Buechler J., Schwab M., Mikus G., Fischer B., Hermle L., Marx C., Gron G., Spitzer M., Kovar K.A. Enantioselective quantitation of the ecstasy compound (R)- and (S)-N-ethyl-3,4-methylenedioxyamphetamine and its major metabolites in human plasma and urine. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 2003, 793:207-222.
3. Capela J.P., Macedo C., Branco P.S., Ferreira L.M., Lobo A.M., Fernandes E., Remiao F., Bastos M.L., Dirnagl U., Meisel A., Carvalho F. Neurotoxicity mechanisms of thioether ecstasy metabolites. Neuroscience 2007, 146:1743-1757.
4. Court M.H., Duan S.X., Guillemette C., Journault K., Krishnaswamy S., von Moltke L.L., Greenblatt D.J. Stereoselective conjugation of oxazepam by human UDP-glucuronosyltransferases (UGTs): S-oxazepam is glucuronidated by UGT2B15, while R-oxazepam is glucuronidated by UGT2B7 and UGT1A9. Drug Metabolism and Disposition: The Biological Fate of Chemicals 2002, 30:1257-1265.
5. De Duve C. Tissue fractionation. Past and present. Journal of Cell Biology 1971, 50:20d-55d.
6. de la Torre R., Farre M. Neurotoxicity of MDMA (ecstasy): the limitations of scaling from animals to humans. Trends in Pharmacological Sciences 2004, 25:505-508.
7. de la Torre R., Farre M., Roset P.N., Pizarro N., Abanades S., Segura M., Segura J., Cami J. Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition [review]. Therapeutic Drug Monitoring 2004, 26:137-144.
8. Easton N., Marsden C.A. Ecstasy: are animal data consistent between species and can they translate to humans? [Review]. Journal of Psychopharmacology 2006, 20:194-210.
9. Esteban B., O'Shea E., Camarero J., Sanchez V., Green A.R., Colado M.I. 3,4-Methylenedioxymethamphetamine induces monoamine release, but not toxicity, when administered centrally at a concentration occurring following a peripherally injected neurotoxic dose. Psychopharmacology (Berlin) 2001, 154:251-260.
10. Freudenmann R.W., Spitzer M. The neuropsychopharmacology and toxicology of 3,4-methylenedioxy-N-ethyl-amphetamine (MDEA). CNS Drug Reviews 2004, 10:89-116.
11. Gollamudi R., Ali S.F., Lipe G., Newport G., Webb P., Lopez M., Leakey J.E., Kolta M., Slikker W. Influence of inducers and inhibitors on the metabolism in vitro and neurochemical effects in vivo of MDMA. Neurotoxicology 1989, 10:455-466.
12. Hutzler J.M., Tracy T.S. Atypical kinetic profiles in drug metabolism reactions. Drug Metabolism and Disposition: The Biological Fate of Chemicals 2002, 30:355-362.
13. Itaaho K., Alakurtti S., Yli-Kauhaluoma J., Taskinen J., Coughtrie M.W., Kostiainen R. Regioselective sulfonation of dopamine by SULT1A3 in vitro provides a molecular explanation for the preponderance of dopamine-3-O-sulfate in human blood circulation. Biochemical Pharmacology 2007, 74:504-510.
14. Itaaho K., Court M.H., Uutela P., Kostiainen R., Radominska-Pandya A., Finel M. Dopamine is a low-affinity and high-specificity substrate for the human UDP-glucuronosyltransferase 1A10. Drug Metabolism and Disposition: The Biological Fate of Chemicals 2009, 37:768-775.
15. Kalant H. The pharmacology and toxicology of ecstasy (MDMA) and related drugs [review]. Canadian Medical Association Journal 2001, 165:917-928.
16. Kiang T.K., Ensom M.H., Chang T.K. UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacology & Therapeutics 2005, 106:97-132.
17. Maurer H.H., Bickeboeller-Friedrich J., Kraemer T., Peters F.T. Toxicokinetics and analytical toxicology of amphetamine-derived designer drugs (Ecstasy). Toxicology Letters 2000, 112:133-142.
18. Mazur A., Lichti C.F., Prather P.L., Zielinska A.K., Bratton S.M., Gallus-Zawada A., Finel M., Miller G.P., Radominska-Pandya A., Moran J.H. Characterization of human hepatic and extrahepatic UDP-glucuronosyltransferase (UGTs) enzymes involved in the metabolism of classical cannabinoids. Drug Metabolism and Disposition: The Biological Fate of Chemicals 2009, 37:1496-1504.
19. Meyer A., Mayerhofer A., Kovar K.A., Schmidt W.J. Enantioselective metabolism of the designer drugs 3,4-methylenedioxymethamphetamine ('ecstasy') and 3,4-methylenedioxyethylamphetamine ('eve') isomers in rat brain and blood. Neuroscience Letters 2002, 330:193-197.
20. Meyer M.R., Maurer H.H. Enantioselectivity in the methylation of the catecholic phase I metabolites of methylenedioxy designer drugs and their capability to inhibit catechol-O-methyltransferase-catalyzed dopamine 3-methylation. Chemical Research in Toxicology 2009, 22:1205-1211.
21. Meyer M.R., Peters F.T., Maurer H.H. The role of human hepatic cytochrome P450 isozymes in the metabolism of racemic 3,4-methylenedioxyethylamphetamine and its single enantiomers. Drug Metabolism and Disposition: The Biological Fate of Chemicals 2009, 37:1152-1156.
22. Monks T.J., Jones D.C., Bai F., Lau S.S. The role of metabolism in 3,4-(+)-methylenedioxyamphetamine and 3,4-(+)-methylenedioxymethamphetamine (ecstasy) toxicity [review]. Therapeutic Drug Monitoring 2004, 26:132-136.
23. Obach R.S., Reed-Hagen A.E. Measurement of Michaelis constants for cytochrome P450-mediated biotransformation reactions using a substrate depletion approach. Drug Metabolism and Disposition: The Biological Fate of Chemicals 2002, 30:831-837.
24. Ohno S., Kawana K., Nakajin S. Contribution of UDP-glucuronosyltransferase 1A1 and 1A8 to morphine-6-glucuronidation and its kinetic properties. Drug Metabolism and Disposition: The Biological Fate of Chemicals 2008, 36:688-694.
25. Paine M.F., Hart H.L., Ludington S.S., Haining R.L., Rettie A.E., Zeldin D.C. The human intestinal cytochrome P450 pie. Drug Metabolism and Disposition: The Biological Fate of Chemicals 2006, 34:880-886.
26. Peters F.T., Kraemer T., Maurer H.H. Drug testing in blood: validated negative-ion chemical ionization gas chromatographic-mass spectrometric assay for determination of amphetamine and methamphetamine enantiomers and its application to toxicology cases. Clinical Chemistry 2002, 48:1472-1485.
27. Peters F.T., Samyn N., Wahl M., Kraemer T., de Boeck G., Maurer H.H. Concentrations and ratios of amphetamine, methamphetamine, MDA, MDMA, and MDEA enantiomers determined in plasma samples from clinical toxicology and driving under the influence of drugs cases by GC-NICI-MS. Journal of Analytical Toxicology 2003, 27:552-559.
28. Schwaninger A.E., Meyer M.R., Barnes A.J., Kolbrich-Spargo E.A., Gorelick D.A., Goodwin R.S., Huestis M.A., Maurer H.H. Human MDMA and phase I and phase II metabolite urinary excretion kinetics following controlled MDMA administration. Clinical Chemistry 2011, 57:1748-1756.
29. Schwaninger A.E., Meyer M.R., Barnes A.J., Kolbrich-Spargo E.A., Gorelick D.A., Goodwin R.S., Huestis M.A., Maurer H.H. Stereoselective urinary MDMA (ecstasy) and metabolites excretion kinetics following controlled MDMA administration to humans. Biochemical Pharmacology 2012, 83:131-138.
30. Schwaninger A.E., Meyer M.R., Huestis M.A., Maurer H.H. Development and validation of LC-HRMS and GC-NICI-MS methods for stereoselective determination of methylenedioxymethamphetamine (MDMA) and its phase I and II metabolites in human urine. Journal of Mass Spectrometry 2011, 46:603-614.
31. Schwaninger A.E., Meyer M.R., Maurer H.H. Investigation on the enantioselectivity of the sulfation of the methylenedioxymethamphetamine (MDMA) metabolites 3,4-dihydroxymethamphetamine (DHMA) and 4-hydroxy-3-methoxymethamphetamine (HMMA) using the substrate depletion approach. Drug Metabolism and Disposition: The Biological Fate of Chemicals 2011, 39:1998-2002.
32. Schwaninger A.E., Meyer M.R., Zapp J., Maurer H.H. The role of human UDP-glucuronyltransferases on the formation of the methylenedioxymethamphetamine (ecstasy) phase II metabolites R- and S-3-methoxymethamphetamine 4-O-glucuronides. Drug Metabolism and Disposition: The Biological Fate of Chemicals 2009, 37:2212-2220.
33. Schwaninger A.E., Meyer M.R., Zapp J., Maurer H.H. Sulfation of the 3,4-methylenedioxymethamphetamine (MDMA) metabolites 3,4-dihydroxymethamphetamine (DHMA) and 4-hydroxy-3-methoxymethamphetamine (HMMA) and their capability to inhibit human sulfotransferases. Toxicology Letters 2011, 202:120-128.
34. Spitzer M., Franke B., Walter H., Buechler J., Wunderlich A.P., Schwab M., Kovar K.A., Hermle L., Gron G. Enantio-selective cognitive and brain activation effects of N-ethyl-3,4-methylenedioxyamphetamine in humans. Neuropharmacology 2001, 41:263-271.
35. Uchaipichat V., Galetin A., Houston J.B., Mackenzie P.I., Williams J.A., Miners J.O. Kinetic modeling of the interactions between 4-methylumbelliferone, 1-naphthol, and zidovudine glucuronidation by udp-glucuronosyltransferase 2B7 (UGT2B7) provides evidence for multiple substrate binding and effector sites. Molecular Pharmacology 2008, 74:1152-1162.
36. Youdim K., Dodia R. Comparison between recombinant P450s and human liver microsomes in the determination of cytochrome P450 Michaelis-Menten constants. Xenobiotica 2010, 40:235-244.